Sorafenib is an oral multikinase inhibitor that inhibits the Ras/Raf/MAPK signaling pathway, as well as platelet-derived growth factor receptors-α and β, VEGFRs-1, 2 and 3 and c-KIT and FLT3 kinases, to prevent tumor growth by antiangiogenic, antiproliferative and/or proapoptotic effects. The gene discussed is FLT3; the disease is neoplasm.